Article Text

Download PDFPDF
Fractalkine (CX3CL1)
  1. Li Wei Huo,
  2. Yong Liang Ye, MMEd,
  3. Guang Wei Wang, MMEd,
  4. Yong Guang Ye, MMed
  1. From the Guangzhou Orthopedic Hospital, Guangzhou, China.
  1. Received August 24, 2014, and in revised form December 13, 2014.
  2. Accepted for publication January 9, 2015.
  3. Reprints: Li Wei Huo, Assistant Professor, Guangzhou Orthopedic Hospital, Dong Feng Middle Rd, No. 449, Yue Xiu District, Guangzhou 510045, China. E-mail: gzohhlw{at}
  4. Li Wei Huo and Yong Liang Ye made same efforts for this paper and should be the joint first authors.

A Biomarker Reflecting Symptomatic Severity in Patients With Knee Osteoarthritis


Background Elevated serum and synovial fluid (SF) fractalkine (CX3CL1) levels have been detected in patients with knee osteoarthritis (OA). The current study was carried out to investigate the association between serum and SF fractalkine levels with symptomatic severity in patients with knee OA.

Method One hundred ninety-three patients with OA and 182 healthy controls were enrolled in this study. The symptomatic severity was assessed by the Western Ontario McMaster University Osteoarthritis scores.

Results Fractalkine levels in SF and serum were both positively associated with self-reported greater pain and physical disability.

Conclusions Fractalkine in SF and serum may serve as a biomarker for reflecting symptomatic severity. Therapeutic interventions that target fractalkine signaling pathways to delay OA-related symptoms deserve further study.

Key Words
  • osteoarthritis
  • fractalkine
  • symptomatic severity
  • biomarker

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.